Alvotech (ALVO) Raw Materials (2022 - 2023)
Alvotech's (ALVO) quarterly Raw Materials came in at $47.8 million in Q2 2023, up 14.0% quarter-over-quarter from $42.0 million in Q4 2022.
Powered by 
Analysis
Alvotech (ALVO) Raw Materials (2022 - 2023) Analysis & Trends
Alvotech (ALVO) has reported Raw Materials for 2 consecutive years, with $47.8 million the latest figure, recorded in Q2 2023.
- For the quarter ending Q2 2023, Raw Materials changed N/A year-over-year to $47.8 million; the trailing twelve-month figure through Jun 2023 stood at $47.8 million (changed N/A YoY), and the FY2022 full-year result was $42.0 million, changed N/A from the prior year.
- Raw Materials advanced to $47.8 million in Q2 2023 per ALVO's latest filing, from $42.0 million in the prior quarter.
- Across five years, Raw Materials topped out at $47.8 million in Q2 2023 and bottomed at $42.0 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn |
| 10 | NutriBand | 72.57 Mn | 69.15 Mn | 181,874.00 |